



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



ESSPL siRNA (m): sc-144950

BACKGROUND

ESSPL (epidermis-specific serine protease-like protein), also known as PRSS48 (protease, serine, 48), is a 328 amino acid secreted protein that belongs to the peptidase S1 family and contains one peptidase S1 domain. Existing as two alternatively spliced isoforms, the gene encoding ESSPL maps to human chromosome 4q31.1. Chromosome 4 represents approximately 6% of the human genome and contains nearly 900 genes. Notably, the Huntingtin gene, which is found to encode an expanded glutamine tract in cases of Huntington's disease, is on chromosome 4. FGFR-3 is also encoded on chromosome 4 and has been associated with thanatophoric dwarfism, achondroplasia, Muenke syndrome and bladder cancer. Chromosome 4 is also tied to Ellis-van Creveld syndrome, methylmalonic acidemia and polycystic kidney disease.

REFERENCES

1. Bonaventure, J., Rousseau, F., Legeai-Mallet, L., Le Merrer, M., Munnich, A. and Maroteaux, P. 1996. Common mutations in the fibroblast growth factor receptor 3 (FGFR 3) gene account for achondroplasia, hypochondroplasia, and thanatophoric dwarfism. *Am. J. Med. Genet.* 63: 148-154.
2. Kalchman, M.A., Graham, R.K., Xia, G., Koide, H.B., Hodgson, J.G., Graham, K.C., Goldberg, Y.P., Gietz, R.D., Pickart, C.M. and Hayden, M.R. 1996. Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. *J. Biol. Chem.* 271: 19385-19394.
3. Howard, T.D., Guttmacher, A.E., McKinnon, W., Sharma, M., McKusick, V.A. and Jabs, E.W. 1997. Autosomal dominant postaxial polydactyly, nail dystrophy, and dental abnormalities map to chromosome 4p16, in the region containing the Ellis-van Creveld syndrome locus. *Am. J. Hum. Genet.* 61: 1405-1412.
4. Singhrao, S.K., Thomas, P., Wood, J.D., MacMillan, J.C., Neal, J.W., Harper, P.S. and Jones, A.L. 1998. Huntingtin protein colocalizes with lesions of neurodegenerative diseases: an investigation in Huntington's, Alzheimer's, and Pick's diseases. *Exp. Neurol.* 150: 213-222.
5. Krakow, D., Salazar, D., Wilcox, W.R., Rimoin, D.L. and Cohn, D.H. 2000. Exclusion of the Ellis-van Creveld region on chromosome 4p16 in some families with asphyxiating thoracic dystrophy and short-rib polydactyly syndromes. *Eur. J. Hum. Genet.* 8: 645-648.
6. Sommardahl, C., Cottrell, M., Wilkinson, J.E., Woychik, R.P. and Johnson, D.K. 2001. Phenotypic variations of orpk mutation and chromosomal localization of modifiers influencing kidney phenotype. *Physiol. Genomics* 7: 127-134.
7. Dobson, C.M., Wai, T., Leclerc, D., Wilson, A., Wu, X., Dore, C., Hudson, T., Rosenblatt, D.S. and Gravel, R.A. 2002. Identification of the gene responsible for the cblA complementation group of vitamin B12-responsive methylmalonic acidemia based on analysis of prokaryotic gene arrangements. *Proc. Natl. Acad. Sci. USA* 99: 15554-15559.
8. Hillier, L.W., Graves, T.A., Fulton, R.S., Fulton, L.A., Pepin, K.H., Minx, P., Wagner-McPherson, C., Layman, D., Wylie, K., Sekhon, M., Becker, M.C., Fewell, G.A., Delehaunty, K.D., Miner, T.L., Nash, W.E., Kremitzki, C., et al. 2005. Generation and annotation of the DNA sequences of human chromosomes 2 and 4. *Nature* 434: 724-731.

CHROMOSOMAL LOCATION

Genetic locus: Prss48 (mouse) mapping to 3 F1.

PRODUCT

ESSPL siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see ESSPL shRNA Plasmid (m): sc-144950-SH and ESSPL shRNA (m) Lentiviral Particles: sc-144950-V as alternate gene silencing products.

For independent verification of ESSPL (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-144950A, sc-144950B and sc-144950C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

ESSPL siRNA (m) is recommended for the inhibition of ESSPL expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor ESSPL gene expression knockdown using RT-PCR Primer: ESSPL (m)-PR: sc-144950-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.